Day One Biopharmaceuticals, Inc.于2018年11月在特拉华州注册成立为一家有限责任公司。作为一家商业化阶段的生物制药公司,该公司专注于开发针对儿童和成人疾病的首创或同类最佳药物。Day One采用搜索与开发战略来识别、收购和推进药物项目,其首个商业化产品是托沃拉非尼(tovorafenib)——一种口服、可穿透血脑屏障、高选择性的II型RAF激酶抑制剂。
董事
名称
职位
Jeremy Bender
Chief Executive Officer, President and Director
Julie Grant
Chair of the Board, Director and Co-Founder
Natalie Holles
Lead Independent Director
Dan Becker
Director
John Josey
Director
Michael Gladstone
Director
Saira Ramasastry
Director
股东
名称
职位
Jeremy Bender
Chief Executive Officer, President and Director
Charles York II
Chief Operating Officer, Chief Financial Officer and Secretary